 The study duration for an individual patient will include a screening period for inclusion of up to 21 days, the treatment period may continue until disease progression, unacceptable adverse reaction or other reason for discontinuation. After study treatment discontinuation an end of treatment EOT visit will be done at approximately 30 days after last study treatment component administration to assess safety and to perform ADA and PK sampling. Then a follow-up visit 60 days after last SAR650984 administration will be done for ADA sampling. If the ADA is positive or inconclusive at Day 60, then ADA will be repeated every 30 days until ADA is negative. Patients who discontinue treatment for reasons other than progression of disease will be followed every month until progression or initiation of subsequent therapy, for a maximum of one year, whichever comes first. 